Startup Originals Team
Bengaluru-based biotechnology firm CrisprBits Private Limited has secured US $3 million in a Pre-Series A funding round, led by the family office Spectrum Impact (of Rajendra Gogri). The round takes the company’s valuation to around US $12 million, enabling it to expand its CRISPR-based diagnostic and gene-editing technology platforms into human health, food-safety and animal-health markets.
Company Background & Technology Focus:
CrisprBits was founded by a team including Bharat Jobanputra, Aditya Sarda, Rajeev Kohli, Sunil Arora and Vijay Chandru, with a mission to “Rewrite Biology and Reimagine the Planet”. The startup develops three key platforms:
- PathCrisp – a molecular diagnostics system for rapid pathogen detection
- EdiCrisp – a gene-editing and strain-engineering platform
- CurieCrisp – a disease-modelling platform for rare genetic conditions
The company’s technology applies CRISPR to areas such as antimicrobial-resistance, food safety, sustainable bio-fuels and personalized therapeutics.
Use of Funds & Growth Strategy:
The newly raised funds will be directed toward:
- Scaling commercialisation of the PathCrisp diagnostics platform, targeting tests for sickle cell disease, typhoid and antimicrobial-resistance in human healthcare.
- Expanding manufacturing capacity for diagnostics in food safety and animal health markets.
- Developing the CRISPR-driven strain-engineering platform, initially focused on bio-fuel production and industrial sustainability.
- Planning global expansion into Africa and Latin America within the next six months for its diagnostic product line.
Why the Investment Matters:
This funding round underscores several emerging trends:
- The growing prominence of synthetic biology and CRISPR-based platforms in India’s deep-tech ecosystem.
- A shift in investor appetite towards biotech ventures addressing high-impact markets like diagnostics, food safety and sustainability.
- India’s biotech sector maturing beyond service-exports into high-value product development, manufacturing and global expansion.
- The alignment of “mission-driven” biotech startups with patient-capital investors willing to back long-term innovation.
Challenges & What to Watch:
While the opportunity is substantial, CrisprBits faces key execution risks:
- Bringing diagnostics and gene-editing products from lab to market requires regulatory approvals, clinical validation and manufacturing scale.
- The global bio-diagnostics market is highly competitive, differentiation, cost-effectiveness and turnaround time will matter.
- Expanding into geographies such as Africa/Latin America presents logistical, regulatory and operational challenges.
- Sustaining long-term funding, product road-map adherence and manufacturing readiness will be critical for credibility and growth.
Final Take:
CrisprBits’ successful raise of US $3 million at a US $12 million valuation marks a significant step for India’s biotech startup ecosystem. With ambitious goals spanning diagnostics, gene editing and sustainability, the company is positioned to become a key player in the global synthetic-biology landscape. Its next chapter will depend on execution, regulatory success and market adoption of its CRISPR-based platforms.
